✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Glenmark Pharmaceuticals Ltd

Common Name
Glenmark Pharmaceuticals
Country
India
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
15,800
Ticker
GLENMARK
Exchange
NATIONAL STOCK EXCHANGE OF INDIA
Description
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company that focuses on developing and marketing innovative medicine. With a robust portfolio of both generic and branded pharmaceuticals, Glen...

Glenmark Pharmaceuticals's Financial Statements Preview

Below are the financial statements of Glenmark Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of INR
2025
2024
Continuing operations
Income
Revenue from operations
133,217.4a
118,130.97a
Other income (net)
1,137.22a
8,399.94a
Total income
134,354.62a
126,530.91a
Expenses
Cost of materials consumed
-30,012.72a
-31,578.22a
Purchases of stock-in-trade
-15,660.03a
-14,511.7a
Changes in inventories of work-in-process, stock-in-trade and finished goods
-2,139.33a
-1,956.22a
Employee benefits expense
-30,220.61a
-28,681.43a
Finance costs
-2,070.65a
-5,159.69a
Depreciation, amortisation and impairment expense
-4,860.1a
-5,819.06a
Other expenses
-35,949.56a
-33,362.53a
Total expenses
-116,634.34a
-117,156.41a
Profit before exceptional items and tax
17,720.28a
9,374.5a
Exceptional items - expense / (income)
3,728.19a
9,009.55a
Profit before tax from continuing operations
13,992.09a
364.95a
Tax expense
Current tax
-3,823.41a
-11,155.52a
Deferred tax
-302.74a
-7,517.93a
Total tax expense
-3,520.67a
-18,673.45a
Profit for the year from continuing operations
10,471.42a
-18,308.5a
Attributable to
Non-controlling interest
0.45a
681.46a
Equity shareholders of Glenmark Pharmaceuticals Limited
10,470.97a
-18,989.96a
Profit before tax from discontinued operations
0a
5,326.92a
Tax expense of discontinued operations
Current tax
0a
-1,284.32a
Deferred tax
0a
-69.32a
Total tax expense
0a
-1,353.64a
Profit for the year from discontinued operations
0a
3,973.28a
Attributable to
Non-controlling interest
0a
0a
Equity shareholders of Glenmark Pharmaceuticals Limited
0a
3,973.28a
Profit/(loss) after tax for the period from continuing and discontinued operations
10,471.42a
-14,335.22a
Non-controlling interest
0.45a
681.46a
Equity shareholders of Glenmark Pharmaceuticals Limited
10,470.97a
-15,016.68a
Limited Data Preview
You are viewing a limited preview of Glenmark Pharmaceuticals’s income statement data. The reported financial values are complete. The full dataset, available for download, additionally includes structured metadata for each line item, such as line item role (line item, subtotal, total) and financial classification (e.g., assets, liabilities, equity, revenue, expenses).
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Glenmark Pharmaceuticals’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Glenmark Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. Glenmark Pharmaceuticals's Integrated Report 2025
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?